SPTLC2 and melanoma: These results were similar to the observation that Sptlc2 deficiency decreased the percentages of tumor-infiltrating T cells among all live CD45+ cells and increased the percentages of T cells expressing the immune checkpoint molecules PD1 and TIGIT in the B16 melanoma model (Supplementary Fig. 7j, k).